Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Chuntao Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-8515-7140; OpenAlex author ID A5102361412. Sources: OpenAlex.

Their work

Papers
30 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2013: 2 papers · 2014: 2 papers · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 6 papers · 2019: 9 papers · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 30

  1. [Corrigendum] RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Co-author DOI 10.3892/ijo.2025.5822↗
  2. Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33410↗
  3. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Co-author DOI 10.1016/j.csbj.2020.11.018↗
  4. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. Co-author DOI 10.1038/s41388-020-01407-8↗
  5. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. Co-author DOI 10.3748/wjg.v26.i8.828↗
  6. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Co-author DOI 10.1002/cam4.1957↗
  7. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2430↗
  8. Angiogenesis in pancreatic cancer: current research status and clinical implications. Co-author DOI 10.1007/s10456-018-9645-2↗
  9. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2018.10.539↗
  10. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6941-4↗
  11. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.2147/cmar.s197911↗
  12. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Co-author DOI 10.2174/0929867325666180413101722↗
  13. The Loss of SMAD4/DPC4 Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. Co-author DOI 10.7150/jca.30883↗
  14. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. Last author DOI 10.7150/jca.32072↗
  15. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis. Co-author DOI 10.1016/j.hbpd.2018.03.007↗
  16. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2018.05.479↗
  17. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  18. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6727-8↗
  19. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Co-author DOI 10.3892/ijo.2018.4269↗
  20. The Significance of Liquid Biopsy in Pancreatic Cancer. Co-author DOI 10.7150/jca.24591↗
  21. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2016.08.005↗
  22. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗
  23. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/m… Co-author DOI 10.1038/srep19222↗
  24. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Co-author DOI 10.18632/oncotarget.6819↗
  25. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  26. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Co-author DOI 10.1016/j.canlet.2015.01.023↗
  27. Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Co-author DOI 10.1007/s00259-014-2688-8↗
  28. Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Co-author DOI 10.1155/2014/925845↗
  29. Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic canc… Co-author DOI 10.1371/journal.pone.0071189↗
  30. Significance of caveolin-1 regulators in pancreatic cancer. Co-author DOI 10.7314/apjcp.2013.14.8.4501↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 30 shared papers, 2013–2026 · strength 2.33
  2. Huaxiang Xu · 29 shared papers, 2013–2026 · strength 2.29
  3. Liang Liu · 22 shared papers, 2013–2026 · strength 1.68
  4. Wenquan Wang · 13 shared papers, 2015–2026 · strength 1.18
  5. Shuo Li · 13 shared papers, 2018–2021 · strength 1.14
  6. Wen-Quan Wang · 16 shared papers, 2013–2020 · strength 1.10
  7. He-Li Gao · 10 shared papers, 2018–2026 · strength 1.01
  8. Shi-Rong Zhang · 10 shared papers, 2018–2026 · strength 1.00
  9. Zi-Hao Qi · 10 shared papers, 2016–2026 · strength 0.94
  10. Jin-Zhi Xu · 9 shared papers, 2018–2026 · strength 0.91
  11. Heli Gao · 9 shared papers, 2018–2021 · strength 0.78
  12. Quanxing Ni · 11 shared papers, 2014–2019 · strength 0.70
  13. Jiang Long · 11 shared papers, 2013–2020 · strength 0.60
  14. Jin Xu · 11 shared papers, 2013–2019 · strength 0.59
  15. Wuhu Zhang · 6 shared papers, 2019–2021 · strength 0.56
  16. Tianjiao Li · 6 shared papers, 2019–2021 · strength 0.56
  17. Liang Liu · 5 shared papers, 2019–2021 · strength 0.46
  18. Chen Liu · 9 shared papers, 2013–2018 · strength 0.44
  19. Hao Li · 4 shared papers, 2019–2021 · strength 0.38
  20. Wei Jin · 5 shared papers, 2018–2019 · strength 0.38
  21. Shirong Zhang · 4 shared papers, 2018–2019 · strength 0.31
  22. Wang Jiang · 3 shared papers, 2020–2021 · strength 0.31
  23. Xuan Han · 3 shared papers, 2020–2021 · strength 0.31
  24. Hao Li · 3 shared papers, 2018–2019 · strength 0.24
  25. Shuai-Shuai Xu · 2 shared papers, 2019–2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.